CLINICAL TRIALS PROFILE FOR FENOFIBRIC ACID

All Clinical Trials for FENOFIBRIC ACID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00300430 ↗	Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.	Completed	Abbott	Phase 3	2006-09-01	The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood.
NCT00300456 ↗	Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood	Completed	Abbott	Phase 3	2006-03-01	The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
NCT00300469 ↗	Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood	Completed	Abbott	Phase 3	2006-03-01	The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
NCT00300482 ↗	Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood	Completed	Abbott	Phase 3	2006-03-01	The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.
NCT00808678 ↗	Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium	Completed	AstraZeneca	Phase 1	2008-12-01	The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
NCT00826358 ↗	Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg	Completed	AstraZeneca	Phase 1	2008-11-01	The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Clinical Trial Conditions for FENOFIBRIC ACID

Condition Name

Condition Name for FENOFIBRIC ACID
Intervention	Trials
Healthy	12
Dyslipidemia	5
Mixed Dyslipidemia	4
Coronary Heart Disease	4

Condition MeSH

Condition MeSH for FENOFIBRIC ACID
Intervention	Trials
Dyslipidemias	5
Coronary Artery Disease	5
Myocardial Ischemia	5
Coronary Disease	4

Clinical Trial Locations for FENOFIBRIC ACID

Trials by Country

Trials by Country for FENOFIBRIC ACID
Location	Trials
United States	13
Korea, Republic of	4
Brazil	1

Trials by US State

Trials by US State for FENOFIBRIC ACID
Location	Trials
Illinois	5
North Dakota	2
Florida	2
Maryland	1
Georgia	1

Clinical Trial Progress for FENOFIBRIC ACID

Clinical Trial Phase

Clinical Trial Phase for FENOFIBRIC ACID
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	5
Phase 1	13

Clinical Trial Status

Clinical Trial Status for FENOFIBRIC ACID
Clinical Trial Phase	Trials
Completed	18
Terminated	2
Unknown status	1

Clinical Trial Sponsors for FENOFIBRIC ACID

Sponsor Name

Sponsor Name for FENOFIBRIC ACID
Sponsor	Trials
Abbott	6
Mutual Pharmaceutical Company, Inc.	6
AstraZeneca	2

Sponsor Type

Sponsor Type for FENOFIBRIC ACID
Sponsor	Trials
Industry	17
Other	5
NIH	1